Meeting
2016 ASCO Annual Meeting
Randomized phase II trial (RENO): efficacy results of oral vinorelbine or etoposide combined with cisplatin in chemo-radiotherapy treatment of locally advanced NSCLC (LA-NSCLC). SLCG 10/02.
Authors
Mariano Provencio
University Hospital Puerta De Hierro, Madrid, Spain
Mariano Provencio , Ramon de las Penas , Amelia Insa , Natividad Martinez-Banaclocha , Raquel Marse Fabregat , Pilar Mut Sanchis , Teresa Moran , Angeles Sala , Bartomeu Massuti , Ana Laura Ortega , Jose Miguel Jurado , Jose Gómez-Codina , Pilar Diz , Angel Artal-Cortes , Vanesa Gutierrez Calderon , Maria Francisca Vazquez , Nuria Vinolas , Miguel Angel Muñoz Quintana , Ramon Garcia-Gomez , Dolores Isla
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Local-Regional Non–Small Cell Lung Cancer
Clinical Trial Registration Number
EudraCT number 2010-022927-31
Citation
J Clin Oncol 34, 2016 (suppl; abstr 8538)
DOI
10.1200/JCO.2016.34.15_suppl.8538
Abstract #
8538
Poster Bd #
166
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
NORA trial (GECP 15/02): First efficacy results of the Spanish Lung Cancer Group (SLCG) phase II trial of concurrent chemo-radiotherapy (CT-RT) with cisplatin (P) plus metronomic oral vinorelbine (mOV) for unresectable locally advanced non-small cell lung cancer (LA-NSCLC).
First Author: Dolores Isla
Poster
2019 ASCO Annual Meeting
Phase II study: Induction chemotherapy and transoral surgery as definitive treatment (Tx) for locally advanced oropharyngeal squamous cell carcinoma (OPSCC)—An update and retrospective review of non-study patients.
First Author: Robert S. Siegel
Poster
2023 ASCO Annual Meeting
Association of immune-related adverse events and efficacy outcomes in phase II trial of consolidation nivolumab plus ipilimumab or nivolumab alone after chemoradiation in patients with unresectable stage III non–small-cell lung cancer (NSCLC).
First Author: Cynthia Wei
Poster
2022 ASCO Gastrointestinal Cancers Symposium
FRONTiER: A feasibility trial of nivolumab with neoadjuvant CF or DCF, FLOT therapy for locally advanced esophageal carcinoma (JCOG1804E)—Short-term results for cohorts C and D.
First Author: Satoru Matsuda